N. Gaynor

Effects of HER Family–targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer

L. Liotta, K. O'Byrne, V. Espina, 2020, Clinical Cancer Research.

Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer.

J. Crown, D. Collins, N. Gaynor, 2020, Seminars in cancer biology.

Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy

B. Hennessy, J. Crown, A. Blanco, 2023, British Journal of Cancer.

HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer

J. Crown, B. Browne, D. Collins, 2018, Investigational New Drugs.